西妥昔单抗治疗非小细胞肺癌的临床疗效

目的：探讨西妥昔单抗治疗非小细胞肺癌患者的临床疗效.方法：收集2007年1月～2008年1月在我院住院治疗的非小细胞肺癌的患者80例,实验组（n=40）给予西妥昔单抗＋顺铂＋紫杉醇;对照组（n=40,顺铂＋紫杉醇.记录治疗前和治疗两个月后的影像、临床资料;观察并记录病人的生存情况和不良反应.结果：影像学检查完全缓解（comlete response,CR）两组均无,部分缓解（partial response,PR）的病人实验组中有10人,对照组有2人,P =0.012;而治疗过程中出现影像学上进展的患者实验组中有8人,对照组组有14人,P =0.133.实验组症状缓解率为26/40,对照组为14/40 ,P = 0.025.结论：西妥昔单抗可安全、有效地用于非小细胞肺癌患者的治疗.临床应用呈现出高临床受益率、高抗肿瘤活性和高安全性的特点,值得临床进一步推广验证.

West proper past Shan Kang treats the non-cellule lung cancer dinical curative effect

Objective： West the discussion proper past Shan Kang treats the non-cellule lung cancer patient＇s clinical curative effect. Methods：West collects in January, 2007 - 2008 year in January in my courtyard hospital treatment non-cellule lung cancer patient 80 examples, the experimental group （n=40） gives the proper past list anti-＋ to be mellow along the platinum ＋ taxus;Control group （n=40,along platinum ＋ taxus mellow. Before after the recording treatment and treats for two months the phantoms, the clinical material;Observes and records patient＇s survival situation and responded not good. Results：The phantom study inspection alleviates （comlete response,CR） two groups not to have completely, the part alleviates （partial response, PR） in the patient experimental group has 10 people, the control group has 2 people,P = 0. 012;But in the course of treatment appears in the patient experimental group which in the phantom study progresses to have 8 people, the control group group has 14 people, P = 0. 133. The experimental group symptom alleviates rate is 26/40, the control group is 14/40P = 0. 025. Conclusion： West proper past Shan Kangke the safety, effectively uses in the non-cellule lung cancer patient＇s treatment. The clinical practice presents the high clinical benefit factor, high anti-tumor activeness and the high secure characteristic, is worth further promoting the confirmation clinically.